Katherine has over 20 years experience as an academic health economist and an international reputation for the economics of precision medicine and genomic technologies and services. Katherine has established a number of innovative research collaborations with genomics and other clinical colleagues. Ongoing and recent projects include: evaluation of information provision and models of informed consent in bloodspot newborn screening programmes; identifying and costing pathways of care for people with ataxia; building economic model to identify the most appropriate interval for breast cancer screening; preliminary economic evaluation of high-throughput whole genome sequencing technologies; towards HTA of whole genome sequencing; economic evaluation of risk stratified breast screening programmes; and various economic evaluations of examples of stratified medicines (funded by NIHR HTA; NIHR Research for Patient Benefit; NIHR Programme Grants for Applied Research; EU Framework Seven; Department of Health; MRC).
Model-based and prospective economic evaluations
Stated preference methods including discrete choice experiments and contingent valuation
Valuing health and non-health outcomes